Compare Nuwellis Inc (NUWE) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Nuwellis Inc trades at $1.48 (market cap $522.76K), while Vanguard Dividend Appreciation Index Fund ETF trades at $245.96. The key difference: Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | VIG | |
|---|---|---|
Market Cap | $522.76K | — |
Sector | Technology | — |
52-Week High | $220.50 | $245.79 |
52-Week Low | $1.42 | $208.67 |
Enterprise Value | -$1.29M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
VIG trades at $245.23, up 0.35% over 24 hours, with a bullish technical signal driven by moving averages and a dividend of $1.00 scheduled for June 2026. The ETF focuses on dividend growth, holding stocks like Broadcom, which has surged 710% over five years (24/7 Wall Street, 2026-07-22).
The outlook is positive for long-term investors seeking steady income, supported by a 20-year dividend growth streak, but risks include high RSI levels indicating overbought conditions and potential market volatility from AI and interest rate uncertainties (Zacks Investment Research, 2026-07-30).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
